ChemAxon Announces new CEO and Head of R&D
News May 13, 2008
ChemAxon, a software solutions provider for cheminformatics, has announced the appointment of Alex Drijver as CEO. The arrival signals the companies increased focus on business development and market position.
Ferenc Csizmadia, founder and former CEO, moves to Chairman and Head of Research and Development. The new R&D position formalizes the bridge between the customer base and the company’s development strategy and in particular the next generation of products under launch.
Alex joins ChemAxon with over 20 years international commercial experience, most recently as CEO and CFO of ThalesNano Inc, a Budapest based manufacturer of novel microfluidic based instruments for chemical synthesis, and CFO of ComGenex, Inc., a chemistry services provider now part of Albany Molecular.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019